This study used a blank control design and included at least 341 subjects. The experimental group and control group were randomized in a 2:1 ratio (at least 228 subjects in the experimental group and at least 113 subjects in the control group). Patients in the experimental group were treated with Huai Er Granules (20g/dose, 3 times/day), while undergoing routine diagnosis and treatment; The control group received routine diagnosis and treatment, but did not take Huaier granules until the subjects experienced disease progression or intolerance.
This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.